Press "Enter" to skip to content

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer – GlobeNewswire

admin 0

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer  GlobeNewswire
“pancreatic cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *